Plus TherapeuticsPSTV 28 Forward PE Ratio is 0.00 as of Jul. 10, 2026. GuruFocus rates PSTV with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 354 Biotechnology companies, Plus Therapeutics ranks worse than 282485.59% on this metric.
Plus Therapeutics (NAS:PSTV) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Plus Therapeutics Forward PE Ratio Related Terms
Plus Therapeutics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Plus Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics Forward PE Ratio Chart
Plus Therapeutics Annual Data
Trend
Forward PE Ratio
Plus Therapeutics Quarterly Data
2016-03
Forward PE Ratio
0.64
PSTV vs KYNB, VTGN, TVGN: Forward PE Ratio Comparison
For the Biotechnology subindustry, Plus Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Plus Therapeutics (PSTV) has a Forward PE Ratio of 0.00 as of Jul. 10, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Plus Therapeutics and its competitors. According to the industry distribution chart, Plus Therapeutics ranks #999999 out of 354 companies in the Biotechnology industry.
Is Plus Therapeutics' Forward PE Ratio too high?
Plus Therapeutics' current Forward PE Ratio is 0.00. Based on the distribution chart, Plus Therapeutics ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Plus Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Forward PE Ratio compare to KYNB and VTGN?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #999999 out of 354 companies for Forward PE Ratio. This places Plus Therapeutics in the lower half of its industry. The industry median Forward PE Ratio is 21.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.90, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Plus Therapeutics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plus Therapeutics's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Plus Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current Forward PE Ratio is 0.00 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
28GF Score
Get the complete analysis for PSTV
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSTV has been successfully added to your 